{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:26:00Z","timestamp":1783077960626,"version":"3.54.6"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Based on our previous study on\n                    <jats:italic>N\u2011<\/jats:italic>\n                    substituted 2-hydroxyiminoacetamides as cholinesterase-targeting ligands, which highlighted 2-hydroxyimino-\n                    <jats:italic>N<\/jats:italic>\n                    -(3-(4-((2-methyl-\n                    <jats:italic>1H<\/jats:italic>\n                    -imidazol-1-yl)methyl)-\n                    <jats:italic>1H<\/jats:italic>\n                    -1,2,3-triazol-1-yl)-1-phenylpropyl)acetamide as lead compound because of its inhibition potency, we extended this group of compounds by introducing a new, bulkier peripheral anionic site (PAS)-binding substituent \u2013 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline to achieve an orientation of its three modular elements that would comply with our initial design: the benzyl unit to occupy the choline binding region, the bulky substituent to stabilise binding at the peripheral site, and the 2-hydroxyiminoacetamide moiety to bind at the catalytic serine residue. The obtained\n                    <jats:italic>N<\/jats:italic>\n                    -(3-(4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(\n                    <jats:italic>1H<\/jats:italic>\n                    )-yl)methyl)-\n                    <jats:italic>1H<\/jats:italic>\n                    -1,2,3-triazol-1-yl)-1-phenylpropyl)-2-(hydroxyimino)acetamide inhibited both human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) non-competitively in a low micromolar range. Molecular docking studies predicted high stability of the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline group at PAS and of the 2-hydroxyiminoacetamide moiety and the benzyl group inside the catalytic site of BChE, while the closest orientation of the three modular elements to our initial design was predicted for AChE, though different orientations were also predicted. Cytotoxicity was observed in the HepG2 and HEK293 cell lines, but only at concentrations exceeding those used in the reversible inhibition assay. Our study confirms\n                    <jats:italic>N<\/jats:italic>\n                    -substituted 2-hydroxiiminoacetamides with three structural elements as low micromolar cholinesterase ligands, successfully extending the scope of PAS substituent to 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. Beyond cholinesterase inhibition, our findings contribute to better understanding of the cytotoxic properties of constituting structural elements of the tested\n                    <jats:italic>N<\/jats:italic>\n                    -(3-(4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(\n                    <jats:italic>1H<\/jats:italic>\n                    )-yl)methyl)-\n                    <jats:italic>1H<\/jats:italic>\n                    -1,2,3-triazol-1-yl)-1-phenylpropyl)-2-(hydroxyimino)acetamide.\n                  <\/jats:p>","DOI":"10.2478\/aiht-2026-77-4078","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:16:08Z","timestamp":1775456168000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Structure-guided modification of a lead cholinesterase-targeting oxime to improve peripheral site binding"],"prefix":"10.2478","volume":"77","author":[{"given":"Nikola","family":"Marakovi\u0107","sequence":"first","affiliation":[{"name":"Institute for Medical Research and Occupational Health , Division of Toxicology , Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1709-6390","authenticated-orcid":false,"given":"Nicolas","family":"Probst","sequence":"additional","affiliation":[{"name":"University of Rouen Normandy , National Institute of Applied Sciences, COBRA Laboratory , Rouen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tena","family":"\u010cade\u017e","sequence":"additional","affiliation":[{"name":"Institute for Medical Research and Occupational Health , Division of Toxicology , Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Zandona","sequence":"additional","affiliation":[{"name":"Institute for Medical Research and Occupational Health , Division of Toxicology , Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_001","doi-asserted-by":"crossref","unstructured":"Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2(6150):1457\u20139. doi: 10.1136\/bmj.2.6150.1457","DOI":"10.1136\/bmj.2.6150.1457"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_002","doi-asserted-by":"crossref","unstructured":"Galdeano C, Viayna E, Arroyo P, Bidon-Chanal A, Blas JR, Mu\u00f1oz-Torrero D, Luque FJ. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 2010;16:2818\u201336. doi: 10.2174\/138161210793176536","DOI":"10.2174\/138161210793176536"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_003","doi-asserted-by":"crossref","unstructured":"Inoue A, Kawai T, Wakita M, Imura Y, Sugimoto H, Kawakami Y. The simulated binding of (+\/\u2212)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]meth yl] -1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses. J Med Chem 1996;39:4460\u201370. doi: 10.1021\/jm950596e","DOI":"10.1021\/jm950596e"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_004","doi-asserted-by":"crossref","unstructured":"Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer\u2019s plaques and tangles. Brain Res 2005;1060:144\u201352. doi: 10.1016\/j.brainres.2005.08.039","DOI":"10.1016\/j.brainres.2005.08.039"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_005","doi-asserted-by":"crossref","unstructured":"Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88\u201393. doi: 10.1006\/nbdi.2001.0462","DOI":"10.1006\/nbdi.2001.0462"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_006","doi-asserted-by":"crossref","unstructured":"Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer\u2019s disease. Neurochem Res 2003;28:515\u201322. doi: 10.1023\/A:1022869222652","DOI":"10.1023\/A:1022869222652"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_007","doi-asserted-by":"crossref","unstructured":"Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993;58:51\u201366. doi: 10.1016\/0163-7258(93)90066-M","DOI":"10.1016\/0163-7258(93)90066-M"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_008","doi-asserted-by":"crossref","unstructured":"Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 2003;22:165\u201390. doi: 10.2165\/00139709-200322030-00004","DOI":"10.2165\/00139709-200322030-00004"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_009","doi-asserted-by":"crossref","unstructured":"Jokanovi\u0107 M, Stojiljkovi\u0107 MP. Current understanding of the application of pyridinium oximes as cholinesterase reactivators in treatment of organophosphate poisoning. Eur J Pharmacol 2006;553:10\u20137. doi: 10.1016\/j.ejphar.2006.09.054","DOI":"10.1016\/j.ejphar.2006.09.054"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_010","doi-asserted-by":"crossref","unstructured":"Radi\u0107 Z, Sit RK, Kovarik Z, Berend S, Garcia E, Zhang L, Amitai G, Green C, Radi\u0107 B, Fokin VV, Sharpless KB, Taylor P. Refinement of structural leads for centrally acting oxime reactivators of phosphylated cholinesterases. J Biol Chem 2012;287:11798\u2013809. doi: 10.1074\/jbc.M111.333732","DOI":"10.1074\/jbc.M111.333732"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_011","doi-asserted-by":"crossref","unstructured":"Kne\u017eevi\u0107 A, Vinkovi\u0107 V, Marakovi\u0107 N, \u0160inko G. Enzyme-catalyzed cascade synthesis of hydroxyiminoacetamides. Tetrahedron Lett 2014;55:4338\u201341. doi: 10.1016\/j.tetlet.2014.06.027","DOI":"10.1016\/j.tetlet.2014.06.027"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_012","doi-asserted-by":"crossref","unstructured":"Marakovi\u0107 N, Kne\u017eevi\u0107 A, Vinkovi\u0107 V, Kovarik Z, \u0160inko G. Design and synthesis of N-substituted-2-hydroxyiminoacetamides and interactions with cholinesterases. Chem Biol Interact 2016;259:122\u201332. doi: 10.1016\/j.cbi.2016.05.035","DOI":"10.1016\/j.cbi.2016.05.035"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_013","doi-asserted-by":"crossref","unstructured":"Marakovi\u0107 N, Kne\u017eevi\u0107 A, Ron\u010devi\u0107 I, Brazzolotto X, Kovarik Z, \u0160inko G. Enantioseparation, in vitro testing, and structural characterization of triple-binding reactivators of organophosphate-inhibited cholinesterases. Biochem J 2020;477:2771\u201390. doi: 10.1042\/BCJ20200192","DOI":"10.1042\/BCJ20200192"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_014","doi-asserted-by":"crossref","unstructured":"Zandona A, Maduni\u0107 J, Mi\u0161 K, Marakovi\u0107 N, Dubois-Geoffroy P, Cavaco M, Mi\u0161eti\u0107 P, Padovan J, Castanho M, Jean L, Renard PY, Pirkmajer S, Neves V, Katalini\u0107 M. Biological response and cell death signaling pathways modulated by tetrahydroisoquinoline-based aldoximes in human cells. Toxicology 2023;494:153588. doi: 10.1016\/j.tox.2023.153588","DOI":"10.1016\/j.tox.2023.153588"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_015","doi-asserted-by":"crossref","unstructured":"Zandona A, Juri\u0107 M, Jean L, Renard PY, Katalini\u0107 M. Assessment of cytotoxic properties of tetrahydroisoquinoline oximes in breast, prostate and glioblastoma cancer cells. Drug Chem Toxicol 2025;48:856\u201363. doi: 10.1080\/01480545.2025.2491534","DOI":"10.1080\/01480545.2025.2491534"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_016","doi-asserted-by":"crossref","unstructured":"Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88\u201395. doi: 10.1016\/0006-2952(61)90145-9","DOI":"10.1016\/0006-2952(61)90145-9"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_017","doi-asserted-by":"crossref","unstructured":"Eyer P, Worek F, Kiderlen D, Sinko G, Stuglin A, Simeon-Rudolf V, Reiner E. Molar absorption coefficients for the reduced Ellman reagent: reassessment. Anal Biochem 2003;312:224\u20137. doi: 10.1016\/S0003-2697(02)00506-7","DOI":"10.1016\/S0003-2697(02)00506-7"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_018","doi-asserted-by":"crossref","unstructured":"Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, Franklin MC, Height JJ. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012;55:10282\u20136. doi: 10.1021\/jm300871x","DOI":"10.1021\/jm300871x"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_019","doi-asserted-by":"crossref","unstructured":"Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003;278:41141\u20137. doi: 10.1074\/jbc.M210241200","DOI":"10.1074\/jbc.M210241200"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_020","doi-asserted-by":"crossref","unstructured":"Zandona A, Marakovi\u0107 N, Mi\u0161eti\u0107 P, Maduni\u0107 J, Mi\u0161 K, Padovan J, Pirkmajer S, Katalini\u0107 M. Activation of (un)regulated cell death as a new perspective for bispyridinium and imidazolium oximes. Arch Toxicol 2021;95:2737\u201354. doi: 10.1007\/s00204-021-03098-w","DOI":"10.1007\/s00204-021-03098-w"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_021","unstructured":"European Collection of Authenticated Cell Cultures (ECACC). Fundamental Ttechniques in Cell Culture: Laboratory Handbook. 4th ed. Darmstadt: Merck KGaA; 2018."},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_022","doi-asserted-by":"crossref","unstructured":"Dighe SN, Deora GS, De la Mora E, Nachon F, Chan S, Parat MO, Brazzolotto X, Ross BP. Discovery and structure\u2013activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. J Med Chem 2016;59:7683\u20139. doi: 10.1021\/acs.jmedchem.6b00356","DOI":"10.1021\/acs.jmedchem.6b00356"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_023","doi-asserted-by":"crossref","unstructured":"Pajk S, Knez D, Ko\u0161ak U, Zorovi\u0107 M, Brazzolotto X, Coquelle N, Nachon F, Colletier JP, \u017divin M, Stojan J, Gobec S. Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes. J Enzyme Inhib Med Chem 2020;35:498\u2013505. doi: 10.1080\/14756366.2019.1710502","DOI":"10.1080\/14756366.2019.1710502"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_024","doi-asserted-by":"crossref","unstructured":"Ko\u0161ak U, Stra\u0161ek Benedik N, Knez D, \u017dakelj S, Trontelj J, Pi\u0161lar A, Horvat S, Bolje A, \u017dnidar\u0161i\u010d N, Grgurevi\u010d N, \u0160vara T, Kljun J, Skrzypczak-Wiercioch A, Lv B, Xiong Y, Wang Q, Bian R, Shao J, Dias J, Nachon F, Brazzolotto X, Stojan J, Sun H, Sa\u0142at K, Gobec S. Lead optimization of a butyrylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease. J Med Chem 2025;68:11693\u2013723. doi: 10.1021\/acs.jmedchem.5c00577","DOI":"10.1021\/acs.jmedchem.5c00577"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_025","doi-asserted-by":"crossref","unstructured":"Ko\u0161ak U, Knez D, Ferjan\u010di\u010d Benetik S, Mastnak Sokolov P, Pi\u0161lar A, Horvat S, Stojan J, Lv B, Zhang W, Wang Y, Wang Q, Igert A, Dias J, Nachon F, Brazzolotto X, Sun H, Gobec S. Chiral switch of a butyrylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease. Chem Biol Interact 2025;420:111670. doi: 10.1016\/j.cbi.2025.111670","DOI":"10.1016\/j.cbi.2025.111670"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_026","doi-asserted-by":"crossref","unstructured":"Ko\u0161ak U, Knez D, Pi\u0161lar A, Horvat S, \u017dakelj S, Igert A, Dias J, Nachon F, Brazzolotto X, Gobec S. N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors. Chem Biol Interact 2025;420:111681. doi: 10.1016\/j.cbi.2025.111681","DOI":"10.1016\/j.cbi.2025.111681"},{"key":"2026070310564045491_j_aiht-2026-77-4078_ref_027","doi-asserted-by":"crossref","unstructured":"Pesaresi A. Mixed and non-competitive enzyme inhibition: underlying mechanisms and mechanistic irrelevance of the formal two-site model. J Enzyme Inhib Med Chem 2023;38(1):2245168. doi: 10.1080\/14756366.2023.2245168","DOI":"10.1080\/14756366.2023.2245168"}],"container-title":["Archives of Industrial Hygiene and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/aiht-2026-77-4078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:58:04Z","timestamp":1783076284000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/aiht-2026-77-4078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/aiht-2026-77-4078"],"URL":"https:\/\/doi.org\/10.2478\/aiht-2026-77-4078","relation":{},"ISSN":["1848-6312"],"issn-type":[{"value":"1848-6312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}